Tag Archives: Merck’s

WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?

With its latest trial win, Eli Lilly and its Chinese partner Innovent Biologics are eyeing an all-important front-line non-small cell lung cancer approval in China for their PD-1 checkpoint inhibitor, Tyvyt. But competition with Merck & Co.’s formidable Keytruda lies ahead. Adding Tyvyt (sintilimab) to Lilly’s Alimta and platinum chemo significantly extended the time to… Read More »

Merck’s cancer meds keep churning amid COVID-19, but vaccines stumble

Earlier this year, Merck warned investors that the COVID-19 pandemic would take a multbillion-dollar bite out of its revenue expectations for 2020. And in the second quarter, that prediction took shape. The pandemic hurt Merck’s pharmaceutical sales by about $ 1.5 billion from April to June, the drugmaker reported, despite continued growth for its cancer medicines. Sales… Read More »